Multi-event January 2019 FDA Recall Cefdinir by Lupin Pharmaceuticals Inc.

This Multi-event Class II drug recall was voluntarily initiated by Lupin Pharmaceuticals Inc. on January 2, 2019 for the product Cefdinir. The FDA reported the reason for recall as cgmp deviations. The product was distributed Nationwide and the recall is currently terminated.

Reported Recall Events

Recall Number: D-0375-2019

Reason for Recall
CGMP Deviations: Product complaints received indicating reconstituted suspension was observed to be thick.
Initiated
01-02-2019
Reported
01-16-2019
Quantity
287,784 bottles

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Lupin Pharmaceuticals Inc.
Nationwide within the United States
Cefdinir for Oral Suspension USP, 125mg/5mL, packaged in a) 60mL (NDC 68180-722-20), b)100mL (NDC 68180-722-10), Rx Only, Manufactured for: Lupin Pharmaceuticals Inc. Baltimore, MD 21202; Manufactured by: Lupin Limited Mandideep 462 046 INDIA

Batch or Lot Expiration Information

Lot# a)
Lot# : F700329, F700330, F700328, Exp. January 2019; F700544, F700545, F700668, F700669, F700670, Exp. March 2019; F700958, Exp. April 2019 b)
Lot# : F700327, F700392, F700393, Exp. January 2019; F700546, F700547, F700664, Exp. March 2019; F700967, Exp. April 2019, F701106, F701107, F701108, F701109, Exp. May 2019.

Recall Number: D-0376-2019

Reason for Recall
CGMP Deviations: Product complaints received indicating reconstituted suspension was observed to be thick.
Initiated
01-02-2019
Reported
01-16-2019
Quantity
287,784 bottles

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Lupin Pharmaceuticals Inc.
Nationwide within the United States
Cefdinir for Oral Suspension USP, 250mg/5mL, packaged in a) 60mL (NDC 68180-723-20), b)100mL (NDC 68180-723-10), Rx Only, Manufactured for: Lupin Pharmaceuticals Inc. Baltimore, MD 21202; Manufactured by: Lupin Limited Mandideep 462 046 INDIA

Batch or Lot Expiration Information

Lot# a)
Lot# : F700343, F700344, F700345, F700346, F700347,F700376, F700377, F700415, F700146,F700417, F700418, Exp. Jan 2019; F700419, F700420, F700492, F700493,F700508,F700665, Exp. February 2019; F700784, Exp. April 2019; b)
Lot# : F700324, F700325, F700326, Exp. January 2019; F700618, F700619, F700620, Exp. February 2019.